Solid Tumor, Microsatellite Instability-High (MSI-H) Solid Tumors, Cutaneous Melanoma, Pancreatic Cancer, Breast Cancer (HR+HER2-)
Conditions
Keywords
PDL1, PD-L1
Brief summary
The main purpose of this study is to evaluate the safety and tolerability of anti-programmed cell death ligand 1 (PD-L1) checkpoint antibody LY3300054 in participants with advanced refractory solid tumors.
Interventions
DRUGLY3321367
Administered IV
DRUGLY3300054
Administered IV
DRUGRamucirumab
Administered IV
DRUGAbemaciclib
Administered orally
DRUGMerestinib
Administered orally
Sponsors
Eli Lilly and Company
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologic or cytologic confirmation of advanced solid tumor. * For LY3300054 + abemaciclib only: No participants with liver metastases. Participants must have normal aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, direct bilirubin. * For LY3300054 + abemaciclib in HR+, HER- breast cancer: * Express at least 1 of the hormone receptors \[HR; estrogen receptor (ER) or progesterone receptor (PR)\] by immunohistochemistry (IHC) to fulfill the requirement for HR+ disease on the primary tumor or metastatic lesion of the breast cancer. ER and PR assays are considered positive if there is at least 1% positive tumor nuclei in their sample as defined in the relevant American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) or local guidelines. * To fulfill the requirement of HER2- disease, a breast cancer must not demonstrate, at initial diagnosis or upon subsequent biopsy, overexpression of HER2 by either IHC or in-situ hybridization (ISH) as defined in the relevant ASCO/CAP or local guidelines. * Most recent HR and HER2 receptor testing should be used to determine eligibility. * Have previously received prior treatment with at least 1 but no more than 3 chemotherapy regimens in the metastatic setting. * Have AST, ALT, GGT, and AP that are ≤2.5x upper limit of normal (ULN) and normal bilirubin (total and direct) regardless of liver involvement. * For LY3300054 + merestinib in pancreatic cancer: * Histologically or cytological confirmed diagnosis of metastatic or locally advanced, unresectable pancreatic adenocarcinoma (excluding other pancreatic malignancies for example, acinar cell carcinomas, adenosquamous carcinomas, and neuroendocrine islet cell neoplasms). * Have had disease progression, be refractory or intolerant to no more than 2 prior systemic regimens. * For LY3300054 + LY3321367 in PD-1/PD-L1-naive, MSI-H/MMR-deficient advanced solid tumors: * Have histologically or cytologically confirmed diagnosis of advanced solid tumor AND shown to be MSI-H or MMR-deficient. * For LY3300054 + LY3321367 in PD-1/PD-L1- resistant/refractory, MSI-H/MMR-deficient advanced solid tumors: * Have histologically or cytologically confirmed diagnosis of advanced solid tumor AND shown to be MSI-H or MMR-deficient. * Prior exposure to PD-1/PD-L1 agent regardless of response. * For Phase 1b LY3300054 monotherapy or combination therapy, no prior treatment with a PD-1 or PD-L1 agent is allowed. * Exception: the LY3321367 combination in participants with PD-1/PD-L1- resistant/refractory, MSI-H, where prior exposure to PD-1/PD-L1 agent required. * For Phase 1a LY3300054 monotherapy or combination therapy, previous immunotherapy is acceptable if the following criteria are met: * Must not have experienced a toxicity that led to permanent discontinuation of prior immunotherapy. * Must have completely recovered or recovered to baseline prior to screening from any prior adverse events (AEs) occurring while receiving prior immunotherapy. * Must not have experienced a Grade ≥3 immune-related AE or an immune-related neurologic or ocular AE of any grade while receiving prior immunotherapy. * Must not have required the use of additional immunosuppressive agents other than corticosteroids for the management of an AE, not have experienced recurrence of an AE if re-challenged, and not currently require maintenance doses of \>10 milligrams prednisone or equivalent per day. * Have at least 1 measurable lesion assessable using standard techniques by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. * Have adequate organ function. * Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale. * Have an estimated life expectancy of ≥12 weeks, in the judgment of the investigator. * Have submitted a tumor tissue sample, as follows: * For participants entering the Phase 1a dose escalation: have submitted, if available, the most recent archival tumor tissue sample. * For those participating ONLY in Phase 1b expansions: Have submitted tumor tissue sample from a newly obtained core or excisional biopsy for a tumor lesion (preferred) or a recent biopsy taken with 3 months prior to study enrollment and following the participants most recent prior systemic treatment and be willing to undergo a biopsy procedure during the study treatment period for collection of additional tumor tissue sample.
Exclusion criteria
* Have a serious concomitant systemic disorder including human immunodeficiency virus (HIV), active hepatitis B virus (HBV), active hepatitis C virus (HCV), active autoimmune disorder or disease requiring high dose of steroids. * Have a bowel obstruction, history or presence of inflammatory enteropathy or extensive intestinal resection or chronic diarrhea. * Have evidence of interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity or active, noninfectious pneumonitis. * Have an active infection requiring systemic therapy. * Have moderate or severe cardiovascular disease. * Have symptomatic or uncontrolled brain metastases, spinal cord compression, or leptomeningeal disease requiring concurrent treatment. * Have received a live vaccine within 30 days before the first dose of study treatment. * Have a significant bleeding disorder or vasculitis or had a Grade ≥3 bleeding episode within 12 weeks prior to enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of Participants with LY3300054 Dose Limiting Toxicities (DLTs) | Baseline through Cycle 1 (Approximately 28 Days) |
Secondary
| Measure | Time frame |
|---|---|
| PK: Cmax of Ramucirumab | Predose Cycle 1 Day 1 Through Follow Up (Approximately 6 Months) |
| PK: Cmax of Abemaciclib | Predose Cycle 1 Day 1 Through Follow Up (Approximately 6 Months) |
| PK: Cmax of Merestinib | Predose Cycle 1 Day 1 Through Follow Up (Approximately 6 Months) |
| PK: Cmax of LY3321367 | Predose Cycle 1 Day 1 Through Follow Up (Approximately 6 Months) |
| Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3300054 | Predose Cycle 1 Day 1 Through Follow Up (Approximately 6 Months) |
| Progression Free Survival (PFS) | Baseline to Measured Progressive Disease or Death (Approximately 12 Months) |
| Duration of Response (DoR) | Date of CR or PR to Date of Measured Progressive Disease or Death Due to Any Cause (Approximately 12 Months) |
| Time to Response (TTR) | Baseline to Date of CR or PR (Approximately 6 Months) |
| Disease Control Rate (DCR): Proportion of Participants who Exhibit Stable Disease (SD), CR or PR | Baseline to Measured Progressive Disease (Approximately 6 Months) |
| Objective Response Rate (ORR): Proportion of Participants With a Complete Response (CR) or Partial Response (PR) | Baseline to Measured Progressive Disease (Approximately 6 Months ) |
Countries
Belgium, Canada, France, South Korea, Spain, Taiwan, United States
Outcome results
None listed